<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28298229</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>A novel benzo-heterocyclic amine derivative N30 inhibits influenza virus replication by depression of Inosine-5'-Monophospate Dehydrogenase activity.</ArticleTitle><Pagination><StartPage>55</StartPage><MedlinePgn>55</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">55</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-017-0724-6</ELocationID><Abstract><AbstractText Label="BACKGROUD">Influenza virus is still a huge threat to the world-wide public health. Host inosine-5'- monophosphate dehydrogenase (IMPDH) involved in the synthesis of guanine nucleotides, is known to be a potential target to inhibit the replication of viruses. Herein, we evaluated antiviral activity of a benzo-heterocyclic amine derivative N30, which was designed to inhibit IMPDH.</AbstractText><AbstractText Label="RESULTS">The results demonstrated that N30 inhibited the replication of H1N1, H3N2, influenza B viruses, including oseltamivir and amantadine resistant strains in vitro. Mechanistically, neuraminidase inhibition assay and hemagglutination inhibition assay suggested that N30 did not directly target the two envelope glycoproteins required for viral adsorption or release. Instead, the compound could depress the activity of IMPDH type II. Based on these findings, we further confirmed that N30 provided a strong inhibition on the replication of respiratory syncytial virus, coronavirus, enterovirus 71 and a diverse strains of coxsackie B virus.</AbstractText><AbstractText Label="CONCLUSIONS">We identified the small molecule N30, as an inhibitor of IMPDH, might be a potential candidate to inhibit the replication of various viruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Linlin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiqiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dajun</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhuorong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jiandong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuhuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. yuhuanlibj@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006571">Heterocyclic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.205</RegistryNumber><NameOfSubstance UI="D007168">IMP Dehydrogenase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="N">Amines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006571" MajorTopicYN="N">Heterocyclic Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007168" MajorTopicYN="N">IMP Dehydrogenase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012136" MajorTopicYN="N">Respiratory Syncytial Viruses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Benzo-heterocyclic amine derivative</Keyword><Keyword MajorTopicYN="N">IMPDH</Keyword><Keyword MajorTopicYN="N">Influenza A virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28298229</ArticleId><ArticleId IdType="pmc">PMC5353780</ArticleId><ArticleId IdType="doi">10.1186/s12985-017-0724-6</ArticleId><ArticleId IdType="pii">10.1186/s12985-017-0724-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marjuki H, et al. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses. J Virol. 2015;89(10):5419&#x2013;5426. doi: 10.1128/JVI.03513-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03513-14</ArticleId><ArticleId IdType="pmc">PMC4442539</ArticleId><ArticleId IdType="pubmed">25740997</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarado-Facundo E, et al. Influenza Virus M2 Protein Ion Channel Activity Helps To Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence during Transport to the Cell Surface. J Virol. 2015;89(4):1975&#x2013;1985. doi: 10.1128/JVI.03253-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03253-14</ArticleId><ArticleId IdType="pmc">PMC4338904</ArticleId><ArticleId IdType="pubmed">25473053</ArticleId></ArticleIdList></Reference><Reference><Citation>Riegger D, et al. The Nucleoprotein of Newly Emerged H7N9 Influenza A Virus Harbors a Unique Motif Conferring Resistance to Antiviral Human MxA. J Virol. 2015;89(4):2241&#x2013;2252. doi: 10.1128/JVI.02406-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02406-14</ArticleId><ArticleId IdType="pmc">PMC4338896</ArticleId><ArticleId IdType="pubmed">25505067</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang IC, et al. Influenza A Virus Neuraminidase Limits Viral Superinfection. J Virol. 2008;82(10):4834&#x2013;4843. doi: 10.1128/JVI.00079-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00079-08</ArticleId><ArticleId IdType="pmc">PMC2346733</ArticleId><ArticleId IdType="pubmed">18321971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, et al. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol. 1993;67(9):5585&#x2013;5594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237962</ArticleId><ArticleId IdType="pubmed">7688826</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranovich T, et al. T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro. J Virol. 2013;87(7):3741&#x2013;3751. doi: 10.1128/JVI.02346-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02346-12</ArticleId><ArticleId IdType="pmc">PMC3624194</ArticleId><ArticleId IdType="pubmed">23325689</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibert CW, et al. Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models. J Virol. 2010;84(21):11219&#x2013;11226. doi: 10.1128/JVI.01424-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01424-10</ArticleId><ArticleId IdType="pmc">PMC2953187</ArticleId><ArticleId IdType="pubmed">20739532</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurt AC, et al. Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation. J Virol. 2009;83(20):10366&#x2013;10373. doi: 10.1128/JVI.01200-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01200-09</ArticleId><ArticleId IdType="pmc">PMC2753113</ArticleId><ArticleId IdType="pubmed">19641000</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas EC, et al. Different Characteristics and Nucleotide Binding Properties of Inosine Monophosphate Dehydrogenase (IMPDH) Isoforms. PLoS ONE. 2012;7(12):e51096. doi: 10.1371/journal.pone.0051096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0051096</ArticleId><ArticleId IdType="pmc">PMC3517587</ArticleId><ArticleId IdType="pubmed">23236438</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow CA, et al. De novo GTP Biosynthesis Is Critical for Virulence of the Fungal Pathogen Cryptococcus neoformans. PLoS Pathog. 2012;8(10):e1002957. doi: 10.1371/journal.ppat.1002957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002957</ArticleId><ArticleId IdType="pmc">PMC3469657</ArticleId><ArticleId IdType="pubmed">23071437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedstrom L. IMP Dehydrogenase: Structure, Mechanism and Inhibition. Chem Rev. 2009;109(7):2903&#x2013;2928. doi: 10.1021/cr900021w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cr900021w</ArticleId><ArticleId IdType="pmc">PMC2737513</ArticleId><ArticleId IdType="pubmed">19480389</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DJ, et al. Synthesis and broad-spectrum antiviral activity of some novel benzo-heterocyclic amine compounds. Molecules. 2014;19(1):925&#x2013;39. doi: 10.3390/molecules19010925.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules19010925</ArticleId><ArticleId IdType="pmc">PMC6271935</ArticleId><ArticleId IdType="pubmed">24434668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ooi EV, Ang PO., Jr Antiviral activities of extracts from Hong Kong seaweeds. J Zhejiang University Science B. 2008;9(12):969&#x2013;976. doi: 10.1631/jzus.B0820154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1631/jzus.B0820154</ArticleId><ArticleId IdType="pmc">PMC2596289</ArticleId><ArticleId IdType="pubmed">19067465</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasekaran D, et al. Identification of Traditional Medicinal Plant Extracts with Novel Anti-Influenza Activity. PLoS ONE. 2013;8(11):e79293. doi: 10.1371/journal.pone.0079293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079293</ArticleId><ArticleId IdType="pmc">PMC3842314</ArticleId><ArticleId IdType="pubmed">24312177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma LL, et al. Antiviral Activities of Several Oral Traditional Chinese Medicines against Influenza Viruses. Evid Based Complement Alternat Med. 2015;2015:367250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4618326</ArticleId><ArticleId IdType="pubmed">26557857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, et al. Characterization of human coronavirus etiology in Chinese adults with acute upper respiratory tract infection by real-time RT-PCR assays. PLoS One. 2012;7(6):e38638. doi: 10.1371/journal.pone.0038638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0038638</ArticleId><ArticleId IdType="pmc">PMC3376151</ArticleId><ArticleId IdType="pubmed">22719912</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi K-S, et al. Preparation and diagnostic utility of a hemagglutination inhibition test antigen derived from the baculovirus-expressed hemagglutinin-neuraminidase protein gene of Newcastle disease virus. J Vet Sci. 2013;14(3):291&#x2013;297. doi: 10.4142/jvs.2013.14.3.291.</Citation><ArticleIdList><ArticleId IdType="doi">10.4142/jvs.2013.14.3.291</ArticleId><ArticleId IdType="pmc">PMC3788154</ArticleId><ArticleId IdType="pubmed">23820164</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MI, et al. Serological Response in RT-PCR Confirmed H1N1-2009 Influenza A by Hemagglutination Inhibition and Virus Neutralization Assays: An Observational Study. PLoS ONE. 2010;5(8):e12474. doi: 10.1371/journal.pone.0012474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012474</ArticleId><ArticleId IdType="pmc">PMC2930007</ArticleId><ArticleId IdType="pubmed">20814575</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott JW, et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest. 2004;113(2):274&#x2013;84. doi: 10.1172/JCI19874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI19874</ArticleId><ArticleId IdType="pmc">PMC311435</ArticleId><ArticleId IdType="pubmed">14722619</ArticleId></ArticleIdList></Reference><Reference><Citation>Waheed Y. Hepatitis C eradication: A long way to go. World J Gastroenterol. 2015;21(43):12510&#x2013;12512. doi: 10.3748/wjg.v21.i43.12510.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i43.12510</ArticleId><ArticleId IdType="pmc">PMC4649134</ArticleId><ArticleId IdType="pubmed">26604658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Pozzo F, et al. Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro. Res Vet Sci. 2010;88(2):339&#x2013;44. doi: 10.1016/j.rvsc.2009.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rvsc.2009.08.010</ArticleId><ArticleId IdType="pubmed">19781726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother. 1986;30(2):201&#x2013;5. doi: 10.1128/AAC.30.2.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.30.2.201</ArticleId><ArticleId IdType="pmc">PMC180518</ArticleId><ArticleId IdType="pubmed">2876677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair V, et al. A heterocyclic molecule with significant activity against dengue virus. Bioorg Med Chem Lett. 2009;19(5):1425&#x2013;7. doi: 10.1016/j.bmcl.2009.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2009.01.031</ArticleId><ArticleId IdType="pmc">PMC2692961</ArticleId><ArticleId IdType="pubmed">19185487</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushina Y, et al. Inhibitory action of polyunsaturated fatty acids on IMP dehydrogenase. Biochimie. 2007;89(5):581&#x2013;90. doi: 10.1016/j.biochi.2007.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2007.01.009</ArticleId><ArticleId IdType="pubmed">17383068</ArticleId></ArticleIdList></Reference><Reference><Citation>Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967&#x2013;72. doi: 10.1038/nature04082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04082</ArticleId><ArticleId IdType="pubmed">16107837</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas E, et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology. 2011;53(1):32&#x2013;41. doi: 10.1002/hep.23985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23985</ArticleId><ArticleId IdType="pmc">PMC3498496</ArticleId><ArticleId IdType="pubmed">21254160</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. Virus Res. 2011;157(1):61&#x2013;70. doi: 10.1016/j.virusres.2011.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2011.02.005</ArticleId><ArticleId IdType="pubmed">21320556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D, et al. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients. Transplantation. 2016;100(3):662&#x2013;9. doi: 10.1097/TP.0000000000000861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000000861</ArticleId><ArticleId IdType="pubmed">26335915</ArticleId></ArticleIdList></Reference><Reference><Citation>Coilly A, et al. News and challenges in the treatment of hepatitis C in liver transplantation. Liver Int. 2016;36(Suppl 1):34&#x2013;42. doi: 10.1111/liv.13017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.13017</ArticleId><ArticleId IdType="pubmed">26725895</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi N, Lamour JM, Hsu DT. The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. Pediatr Transplant. 2015;19(6):618&#x2013;22. doi: 10.1111/petr.12542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/petr.12542</ArticleId><ArticleId IdType="pubmed">26082342</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>